ArticleRespiration; international review of thoracic diseases2026
Lung Function Impairment after Mild SARS-CoV-2 Infection in Previously Healthy Individuals.
Article in Respiration; international review of thoracic diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
<p>Introduction: The physiological basis for dyspnea, a hallmark of post-COVID syndrome (PCS), remains poorly understood.
methodsIn this analysis of the prospective, multicenter, population-based, longitudinal COVIDOM study, we studied 936 previously healthy adults assessed ≥6 months after a mostly mild, PCR-confirmed SARS-CoV-2 infection. Participants underwent comprehensive pulmonary function testing including spirometry, body plethysmography, diffusing capacity for carbon monoxide, and airwave oscillometry. Dyspnea was assessed by questionnaires (mMRC ≥1/MDP-A1 domain ≥1). We performed cross-sectional and longitudinal analyses for lung function in relation to both dyspnea and a previously defined PCS severity score (PCS-S).
resultsBetween 11/2020 and 05/2023, we examined 936 previously healthy COVIDOM participants (median age 37 [IQR 28-51], 56% female). Dyspnea prevalence increased significantly with PCS severity (low PCS-S: 19.3%; intermediate PCS-S: 53.8%; high PCS-S: 81.8%; p < 0.001). Women suffered more frequently from dyspnea and PCS. Small airway dysfunction (SAD), as indicated by abnormal R5-20 Hz or AX5 Hz measures, tended to be more frequent in participants with high PCS severity and dyspnea compared to those with low PCS and no dyspnea (37% vs. 25%, p = 0.058) with corresponding R5-20 Hz of 0.03 [0.01-0.07] vs. 0.01 [0-0.03] kPa·L-1·s-1 (p < 0.01). Longitudinally, however, none of the baseline or follow-up lung function parameters, including measures of SAD, differed between participants with persistent dyspnea and those who became asymptomatic.
conclusionOscillometry-derived R5-R20 Hz differed significantly between dyspneic PCS patients and controls. The high frequency of SAD and the absence of longitudinal improvement might indicate the potential clinical relevance of SAD assessment, despite its only numeric differences between PCS severity groups. </p>.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.